

# Asymptotic Features of Parallel Agent-Based Immunological System

Aleksander Byrski  
Dept. of Computer Science  
AGH Univ. of Science and Technology  
Al. Mickiewicza 30  
30-059 Kraków, Poland  
Email: olekb@agh.edu.pl

Robert Schaefer  
Dept. of Computer Science  
AGH Univ. of Science and Technology  
Al. Mickiewicza 30  
30-059 Kraków, Poland  
Email: schaefer@agh.edu.pl

Maciej Smółka  
Inst. of Computer Science  
Jagiellonian University,  
ul. Łojasiewicza 6,  
30-348 Kraków, Poland  
Email: smolka@ii.uj.edu.pl

## KEYWORDS

multi-agent systems, Markov chain modeling, ergodicity, global optimization

## ABSTRACT

In the course of the paper we recall the Markov model for immunological Evolutionary Multi-Agent System. The model allows to study asymptotic features of the computation, such as e.g. asymptotic guarantee of success and may lead to better understanding of the structure and dynamics of the considered classes of systems. The main contribution of a paper is an outline of a proof of the ergodicity feature of the Markov chain modeling iEMAS dynamics.

## INTRODUCTION

The formal model presented by Vose (Vose, 1998) proved in the most simple, yet effective way, asymptotic guarantee of success (Horst and Pardalos, 1995; Rinnoy Kan and Timmer, 1987) in the analysis of the simple genetic algorithm (SGA) behavior, formally confirming the possibility of using SGA for global optimization. Formal models for genetic algorithms were also proposed by other researchers, providing a deeper insight into the long term, steady state behavior of large population EAs (Davis and Principe, 1991; Suzuki, 1993; Rudolph, 1994) or modeling specific features of EAs such as selection, genetic drift, niching etc. (Goldberg and Segrest, 1987; Mahfoud, 1991; Horn, 1993). Many other, more complex, biologically-inspired computational techniques were proposed (e.g. memetic systems, immune-inspired systems), however, the problem of construction of appropriate mathematical models and approaches at proving asymptotic guarantee of success do not seem to be studied extensively or even were not undertaken at all.

In the course of paper we recall the basic features of the stochastic Markov models already introduced in the works of Byrski et al. (e.g. (Byrski and Schaefer, 2009; Schaefer et al., 2009)). We define the space of states, synchronization mechanism, and we draw the probability transition function. The main contribution of the paper is a draft of the sequence of actions proving the ergodicity of Markov chain constructed for iEMAS (immunological Evolutionary Multi Agent System introduced by Byrski

and Kisiel-Dorohinicki (Byrski and Kisiel-Dorohinicki, 2005)) by transferring the system between two arbitrarily chosen states. The formal proof for EMAS (predecessor of iEMAS, being a general optimization system leveraging paradigms of evolutionary computation and agency, introduced by Cetnarowicz (Cetnarowicz et al., 1996)) ergodicity has already been submitted for publication, we will follow with iEMAS ergodicity in the near future.

## AGENT-BASED MANAGEMENT AND SYNCHRONIZATION

We start considerations from evolutionary multi-agent systems solving global optimization problems (cf. (Schaefer et al., 2009)), which consist of finding all global minimizers of a given nonnegative fitness function  $FITN$  over a finite genetic universum  $U$  with cardinality  $r$ . EMAS agents belong to a predefined finite set  $Ag$ . Every active agent is assigned to a location (island) from the set  $Loc = \{1, \dots, s\}$ . The locations are interconnected with channels along which agents can migrate. A channel topology is given by a symmetric relation  $Top \subset Loc^2$ .

Continuing considerations presented in e.g. (Byrski and Schaefer, 2009; Schaefer et al., 2009) we focus on the *Immunologically based Evolutionary Multi-Agent System* (iEMAS) that contains (besides dynamic collection of agents that belong to the predefined finite set  $Ag$  identical to the one of EMAS) a dynamic collection of lymphocytes that belong to the finite set  $Tc$ . Lymphocytes are unambiguously indexed by the genotypes from  $U$ , so that  $\#Tc = \#U = r$ .

The lymphocytes have a similar structure as the agents previously defined, however, their actions differ (because their goals differ from the agents' goals) and their total energy does not have to be constant.

iEMAS may be modeled as the following tuple:

$$\langle U, \{P_i\}_{i \in Loc}, Loc, Top, Ag, \{agsel_i\}_{i \in Loc}, locsel, \{LA_i\}_{i \in Loc}, MA, \omega, Act, \{typesel_i\}_{i \in Loc}, \{tcsel_i\}_{i \in Loc}, Tc, Tcact \rangle \quad (1)$$

where:

- $MA$  (master agent) is used to synchronize the work of the locations; it allows to perform actions in particular locations. This agent is also used to introduce necessary synchronization into the system.

- $locsel : X \rightarrow \mathcal{M}(Loc)$  is the function used by  $MA$  to determine which location should be allowed to perform the next action,
- $LA_i$  (local agent) is assigned to each location; it is used to synchronize the work of computational agents present in its location,  $LA_i$  chooses the computational agent and lets it evaluate a decision and perform the action, at the same time asking  $MA$  whether this action may be performed.
- $agsel_i : X \rightarrow \mathcal{M}(U \times P_i)$  is a family of functions used by local agents to select the agent that may perform the action, so every location  $i \in Loc$  has its own function  $agsel_i$ . The probability  $agsel_i(x)(gen, n)$  vanishes when the agent  $ag_{gen,n}$  is inactive in the state  $x \in X$  or when it is present in a location other than  $i$ -th one,
- $\omega : X \times U \rightarrow \mathcal{M}(Act)$  is the function used by agents for selecting actions from the set  $Act$ ; both these symbols will be described later.
- $Act$  is a predefined, finite set of actions.
- $typesel_i$  is a function used to select the type of agent in  $i$ -th location to interact with the system in the current step,
- $tcsel_i$  is used to choose a lymphocyte in  $i$ -th location to interact with the system in the current step,
- $\varphi$  is the decision function for lymphocytes,
- $Tcact$  is a set of actions that may be performed by lymphocytes.

Hereafter  $\mathcal{M}(\Omega)$  shall stand for the space of probabilistic measures over  $\Omega$ .

In order to design a Markov model of the system with relaxed synchronization (i.e. such that agents present in different locations may act in parallel), a timing mechanism must be introduced, i.e. all state changes must be assigned to subsequent time moments  $t_0, t_1, \dots$

In Fig. 1 the scheme of the synchronization mechanism built using agents,  $LA_i, i \in Loc$  and  $MA$  is presented.

The computational agent  $CA = ag_{gen,n}$  present in the location  $i$  in every observable time moment chooses an action it wants to perform and asks its supervisor (local agent  $LA_i$ ) for a permission to carry on. Then it suspends its work waiting for the permission. When the permission is granted and the decision assigned to the considered action is positive, the computational agent changes the state of the location. Afterwards the agent suspends its work again in order to get a permission to perform a subsequent action. The immunological agent  $TC$  works in a similar way to  $CA$ , managing behavior of a single lymphocyte.

The local agent  $LA_i$  receives signals containing actions to be performed from all its agents. Then chooses




Figure 1: Scheme of the synchronization mechanism

one computational agent which should try to perform its action. This action is reported to the master agent  $MA$  and after receiving permission, the computational agent can perform the action. All other agents are stopped from performing their actions.

The master agent waits for all requests from location and then chooses randomly one location. If this location asks for permission to perform global action, then it is granted this permission and all other locations are rejected. Otherwise all locations which asked for the permission to perform global action are rejected and all those asking for permission to perform local action – are granted.

## SYSTEM STATE

In this section we cite the description of EMAS state and extend it by adding a matrix describing iEMAS state (following (Schaefer et al., 2009)).

## EMAS STATE

Let us introduce the set of three-dimensional, incidence and energy matrices  $x \in X$  with  $s$  layers (corresponding to all locations)  $x(i) = \{x(i, gen, n), gen \in U, n \in P_i\}$ ,  $i \in Loc$ . The layer  $x(i)$  will contain energies of agents in  $i$ -th location. In other words, if  $x(i, gen, k) > 0$ , it means that the  $k$ -th clone of the agent containing the gene  $gen \in U$  is active, its energy equals  $x(i, gen, k)$  and it is located in  $i$ -th location.

We introduce the following coherency conditions:

- $(\cdot, j, k)$ -th column contains at most one value greater than zero, which expresses that the agent with  $k$ -th copy of  $j$ -th genotype may be present in only one location at a time, whereas other agents containing copies of  $j$ -th genotype may be present in other locations;
- incidence and energy matrices' entries are non-negative  $x(i, j, k) \geq 0$ ,  $\forall i = 1, \dots, s, j = 1, \dots, r, k = 1, \dots, p$  and

$\sum_{i=1}^s \sum_{j=1}^r \sum_{k=1}^p x(i, j, k) = 1$ , which means that total energy contained in the whole system is constant, equal to 1;

- each layer  $x(i)$  contains at most  $q_i$  values greater than zero, which denotes the maximum capacity of the  $i$ -th location, moreover, the quantum of energy  $\Delta e$  is lower or equal than total energy divided by the maximal number of individuals that may be present in the system

$$\Delta e \leq \frac{1}{\sum_{i=1}^s q_i}. \quad (2)$$

which allows us to achieve maximal population of agents in the system;

- reasonable values of  $p$  should be greater or equal to 1 and less or equal to  $\sum_{i=1}^s q_i$ ; we assume that  $p = \sum_{i=1}^s q_i$  which assures that each configuration of agents in locations is available, respecting the constrained total number of active agents  $\sum_{i=1}^s q_i$ ; increasing  $p$  over this value does not enhance the descriptive power of the presented model;
- the maximal number of copies for each location  $\#P_i$  should not be less than  $q_i$ , because we want to allow a system state in which a particular location is filled with clones of one agent; obviously increasing  $\#P_i$  over  $q_i$  is only a formal constraint relaxation, so finally we assume that  $\#P_i = q_i$ .

Gathering all these conditions, the set of three-dimensional incidence and energy matrices may be described in the following way.

$$\Lambda = \left\{ \begin{aligned} &ince \in \{0, \Delta e, 2 \cdot \Delta e, 3 \cdot \Delta e, \dots, m \cdot \Delta e\}^{s \cdot r \cdot p}, \\ &\Delta e \cdot m = 1, \\ &\sum_{i=1}^s \sum_{j=1}^r \sum_{k=1}^p x(i, j, k) = 1, \\ &\forall i = 1, \dots, s: \sum_{j=1}^r \sum_{k=1}^p [x(i, j, k) > 0] \leq q_i, \\ &\forall i = 1, \dots, s, j = 1, \dots, r, k \notin P_i: x(i, j, k) = 0, \\ &\forall j = 1, \dots, r, k = 1, \dots, p: \sum_{i=1}^s [x(i, j, k) > 0] \leq 1 \end{aligned} \right\} \quad (3)$$

where  $[\cdot]$  denotes the value of the logical expression contained in the parentheses.

### iEMAS STATE

In addition to the EMAS state describing the location and energy of agents (see (??)), we need to consider a set of matrices containing similar information for lymphocytes. Yet there is no need to assure the constant total energy for

lymphocytes. We describe this additional set of lymphocyte incidence and energy matrices in the following way:

$$\Gamma = \left\{ \begin{aligned} &tcince \in [0, \Delta e, 2 \cdot \Delta e, \dots, n \cdot \Delta e]^{r \cdot s}: \\ &\forall i = 1, \dots, s \sum_{j=1}^r [tcince(i, j) > 0] \leq tcq_j \\ &\text{and } \forall j = 1, \dots, r \sum_{i=1}^s [tcince(i, j) > 0] \leq 1 \end{aligned} \right\} \quad (4)$$

where  $tcince(i, j)$  stands for energy of  $tc_j$  being active in the location  $i$ . The integers  $tcq_j$ ,  $j = 1, \dots, s$  stand for the maximum number of lymphocytes in particular locations. It is most convenient to assume  $tcq_j = q_j$ ,  $\forall j = 1, \dots, s$ .

The space of iEMAS states is defined as follows:

$$X = \Delta \times \Gamma \quad (5)$$

### SYSTEM BEHAVIOR

Let us denote by  $X_{gen}$  the subset of states in which there are active agents with genotype  $gen \in U$  or an active lymphocyte.

### EMAS BEHAVIOR

Each action  $\alpha \in Act$  will be represented as the pair of function families  $(\{\delta_\alpha^{gen}\}_{gen \in U}, \{\vartheta_\alpha^{gen}\}_{gen \in U})$ . The functions

$$\delta_\alpha^{gen}: X \rightarrow \mathcal{M}(\{0, 1\}) \quad (6)$$

represent the decision to be taken: whether the action can be performed or not. The action  $\alpha$  is performed with the probability  $\delta_\alpha^{gen}(x)(1)$  by the agent  $ag_{gen,n}$  at the state  $x \in X$  and rejected with the probability  $\delta_\alpha^{gen}(x)(0)$ .

Next, the formula

$$\vartheta_\alpha^{gen}: X \rightarrow \mathcal{M}(X) \quad (7)$$

defines the non-deterministic state transition functions, so that  $\vartheta_\alpha^{gen}$  is caused by the execution of the action  $\alpha$  by the agent  $ag_{gen,n}$ . Because the function is invoked only if the agent is active, it is enough to define its restriction  $\vartheta_\alpha^{gen}|_{X_{gen}}$  and take an arbitrary value on  $X \setminus X_{gen}$ .

If any action is rejected, the trivial state transition

$$\vartheta_{null}: X \rightarrow \mathcal{M}(X) \quad (8)$$

such that for all  $x \in X$

$$\vartheta_{null}(x)(x') = \begin{cases} 1 & \text{if } x = x' \\ 0 & \text{otherwise} \end{cases} \quad (9)$$

is performed.

The probability transition function for the action  $\alpha$  performed by the agent containing the genotype  $gen$

$$\varrho_\alpha^{gen}: X \rightarrow \mathcal{M}(X) \quad (10)$$

is given by the formula

$$\begin{aligned} \varrho_{\alpha}^{gen}(x)(x') &= \delta_{\alpha}^{gen}(x)(0) \cdot \vartheta_{null}(x)(x') \\ &+ \delta_{\alpha}^{gen}(x)(1) \cdot \vartheta_{\alpha}^{gen}(x)(x') \end{aligned} \quad (11)$$

where  $x \in X$  denotes a current state and  $x' \in X$  a consecutive state resulted from the conditional execution of  $\alpha$ .

### iEMAS BEHAVIOR

We introduce the function  $typesel_i$  choosing which type of agents will have the possibility of performing the action:

$$typesel_i : X \rightarrow \mathcal{M}\{0, 1\} \quad (12)$$

when 0 is chosen, one of the agents is activated, when 1 — the lymphocyte.

The function choosing which agent will be activated  $agsel_i$  is like in EMAS but it now depends in some way on the extended state from  $X$  defined by (5). Now we introduce a new function that will choose which lymphocyte will be activated:

$$tcsel_i : X \rightarrow \mathcal{M}(Tc) \quad (13)$$

Similarly, as in the case of  $agsel_i$  the probability  $tcsel_i(x)(\{gen\})$  vanishes when the lymphocyte  $tc_{gen}$  is inactive in the state  $x \in X$ .

The function  $\omega$  choosing the action for the active agent remains intact, though its domain changes (because of the new state definition, see (5)).

The function choosing the action for the active lymphocyte is the following:

$$\varphi : U \times X \rightarrow \mathcal{M}(Tcact) \quad (14)$$

We will use the family of functions  $\eta_{\alpha}^{gen} : X \rightarrow \mathcal{M}(X)$  where  $gen \in U$ ,  $\alpha \in Tcact$ . Each of them expresses the probability transition imposed by the lymphocyte  $tc_{gen}$  that performs the action  $\alpha \in Tcact$ . They are given by the general formula:

$$\begin{aligned} \eta_{\alpha}^{gen}(x)(x') &= \gamma_{\alpha}(gen, x)(\{0\}) \cdot \vartheta_{null}(x)(x') \\ &+ \gamma_{\alpha}(gen, x)(\{1\}) \cdot \kappa_{\alpha}^{gen, n}(x)(x') \end{aligned} \quad (15)$$

### COMMUTATIVITY OF ACTIONS

The agents' and lymphocytes' actions may be divided into two distinct types:

- global – they change the state of the system in two or more locations, so only one global action may be performed at a time,
- local – they change the state of the system inside one location respecting only the state of local agents, only one local action for one location may be performed at a time.

Therefore we divide the *Act* set in the following way:

$$Act = Act_{gl} \cup Act_{loc} \quad (16)$$

and accordingly, *Tcact*:

$$Tcact = Tcact_{gl} \cup Tcact_{loc} \quad (17)$$

Speaking informally, local actions (elements of  $Act_{loc}, Tcact_{loc}$ ) change only the entries of the layer  $x(i)$  of the incidence and energy matrices if the location  $i \in Loc$  contains the agent performing a certain action. Moreover, these actions do not depend on other layers of  $x$ . The action *null* is obviously “the most local one”, because it does not change anything at all.

The above description can be formalized and the feature of commutativity may be easily proven (cf. (Byrski and Schaefer, 2009; Schaefer et al., 2009)), however here we have to skip the proof due to publishing constraints.

### PARALLEL iEMAS DYNAMICS

At the observable moment at which EMAS takes the state  $x \in X$  all agents in all locations notify their local agents their intent to perform an action, all local agents choose an agent with the distribution given by the  $agsel_i(x)$ ,  $i \in Loc$  function and then notify the master agent of their intent to let perform an action by one of their agents. The master agent chooses the location with the probability distribution given by  $locsel(x)$ .

We extend the model of EMAS dynamics in order to model the behavior of iEMAS. The probability that in the chosen location  $i \in Loc$  the agent or lymphocyte wants to perform local action is as follows:

$$\begin{aligned} \xi_i(x) &= typesel(x)(\{0\}) \sum_{gen \in U} \sum_{n=1}^p (agsel_i(x)(\{gen, n\}) \\ &\cdot \omega(gen, x)(Act_{loc})) + typesel(x)(\{1\}) \end{aligned} \quad (18)$$

The probability that the master agent will chose the location with the agent intending to perform the local action is:

$$\zeta^{loc}(x) = \sum_{i \in Loc} locsel(x)(\{i\}) \xi_i(x) \quad (19)$$

of course the probability of choosing the global action by the master agent is:

$$(1 - \zeta^{loc}(x)) = \zeta^{gl}(x) \quad (20)$$

If the global action is chosen, the state transition is given by:

$$\begin{aligned} \tau^{gl}(x)(x') &= \sum_{i \in Loc} locsel(x)(\{i\}) \cdot \\ &\left( \sum_{gen \in U} \sum_{n=1}^p agsel(x)(\{gen, n\}) \cdot \right. \\ &\left. \left( \sum_{\alpha \in Act_{gl}} \omega(gen, x)(\{\alpha\}) \cdot \varrho_{\alpha}^{gen, n}(x)(x') \right) \right) \end{aligned} \quad (21)$$

Let us state the set of action sequences containing at least one local action:

$$Act_{+1loc} = \left\{ (\alpha_1, \dots, \alpha_s) \in (Act \cup Tcact)^s; \right. \\ \left. \sum_{i=1}^s [\alpha_i \in (Act_{loc} \cup Tcact)] > 0 \right\} \quad (22)$$

The probability that in  $i$ -th location the agent  $ag_{gen_i, n_i}$  or the lymphocyte  $tc_{\widetilde{gen}_i}$  chooses the action  $\alpha_i$  is given by:

$$\mu_{\alpha_i, gen_i, n_i, \widetilde{gen}_i}(x) = \\ typesel(x)(\{0\}) \cdot agsel_i(x)(\{gen_i, n_i\})\omega(gen_i, x)(\{\alpha_i\}) + \\ typesel(x)(\{1\})ttsel_i(x)(\{\widetilde{gen}_i\})\varphi(\widetilde{gen}_i, x)(\{\alpha_i\}) \quad (23)$$

Let us define a multi-index:

$$ind = (\alpha_1, \dots, \alpha_s; (gen_1, n_1), \dots, (gen_s, n_s); \\ (\widetilde{gen}_1), \dots, (\widetilde{gen}_s)) \\ \in IND = (Act \cup Tcact)^s \times (U \times \{1, \dots, p\})^s \times U^s \quad (24)$$

the probability that in consecutive locations agents  $ag_{gen_i, n_i}$  or lymphocytes  $tc_{\widetilde{gen}_i}$  will choose the actions  $\alpha_i$  is given by:

$$\mu_{ind}(x) = \prod_{i=1}^s \mu_{\alpha_i, gen_i, n_i, \widetilde{gen}_i}(x). \quad (25)$$

Transition function for parallel system is following:

$$\tau^{loc}(x)(x') = \sum_{(\alpha_1, \dots, \alpha_s) \in Act_{+1loc}} \sum_{ind \in IND} \\ \mu_{ind}(x)(\pi_1^{ind}(x) \circ \dots \circ \pi_s^{ind}(x))(x') \quad (26)$$

where  $\pi_i$  is defined as:

$$\pi_i^{ind}(x) = \begin{cases} \varrho_{\alpha_i}^{gen_i, n_i}(x), & \alpha_i \in Act_{loc} \\ \eta_{\alpha_i}^{\widetilde{gen}_i}(x), & \alpha_i \in Tcact \\ \vartheta_{null}, & \alpha_i \in Act_{gl} \end{cases} \quad (27)$$

Let us observe again that the value of  $(\pi_1^{ind}(x) \circ \dots \circ \pi_s^{ind}(x))(x')$  does not depend on the composition order, because transition functions associated with local actions commute pairwise. Finally, we may derive the following observation.

**Observation 1.** *The probability transition function for the parallel iEMAS model is given by the formula*

$$\tau(x)(x') = \zeta^{gl}(x)\tau^{gl}(x)(x') + \zeta^{loc}(x)\tau^{loc}(x)(x') \quad (28)$$

and formulas (18) – (27).

**Observation 2.** *The stochastic state transition of iEMAS given by formula (28) satisfies the Markov condition.*

*Proof.* All transition functions and probability distributions given by formulas (18)–(27) depend only on the current state of the system, which motivates the Markovian features of the transition function  $\tau$  given by (28). The transition functions do not depend on the number of step at which is applied what motivates the stationarity of the chain.  $\square$

## LOCAL AND GLOBAL ACTIONS IN iEMAS

Let us consider the following set of actions for EMAS

$$Act = \{get, repr, clo, migr\} \quad (29)$$

where

- *get* allows the better agent to take a certain part of the life energy from the worse agent (possibly making the agent with low energy inactive and activating a lymphocyte containing its genotype), the distinction between ‘better’ and ‘worse’ agent is made based on the value of the fitness function counted for their genotypes,
- *repr* and *clo* activate an agent as the offspring agent in the system based on the genotypes of two parents or one parent accordingly, if the energy of an agent raises over a certain level it may produce a clone or find a partner and reproduce,
- *migr* denotes migration of agents between the two locations, agent with certain amount of energy may move to another island.

The set of actions designed for lymphocytes is

$$Tcact = \{give, kill\} \quad (30)$$

where:

- *give* is the action of the lymphocyte used to decrease its own energy (performed during each activation), which in the end causes the lymphocyte to be deactivated (when its energy reaches zero),
- *kill* is the action of removing the computational agent by the lymphocyte (performed when the genotype of the tested agent matches the pattern contained in the lymphocyte).

The detailed descriptions of decisions and state transition functions for these actions may be found in (Byrski and Schaefer, 2009) along with proofs of their markovian features.

## iEMAS ERGODICITY PROOF DRAFT

In this section we present a draft of ergodicity proof for Markov chain describing the behavior of iEMAS.

**Theorem 1.** *Given the following assumptions:*

1. The migration energy threshold is lower than the total energy divided by the number of locations  $e_{migr} < \frac{1}{s}$ . This assumption ensures that there will be at least one location in the system in which an agent is capable of performing migration (by gathering enough energy from its neighbors).
2. The quantum of energy is lower than or equal to the total energy divided by the maximum number of agents that may be present in the system  $\Delta e \leq \frac{1}{\sum_{i=1}^s q_i}$ . This assumption allows to achieve a maximal population of agents in the system.
3. Reproduction (cloning) energy is lower than two energy quanta  $e_{repr} \leq 2\Delta e$ .
4. The amount of energy passed from parent to the child during action *clo* is equal to  $\Delta e$  (so  $n_1 = 1$ ).
5. The maximum number of agents on every location is greater than one,  $q_i > 1, i = 1, \dots, s$ .
6. Locations are totally connected, i.e.  $Top = Loc^2$ .
7. Each active agent can be selected by its local agent with strictly positive probability.
8. The families of probability distributions being the parameters of EMAS have uniform, strictly positive lower bounds.

Then, the Markov chain modeling iEMAS –see equation (28)– is ergodic.

In order to prove the Theorem 1, it is enough to prove that the passage from  $x_b$  to  $x_e$  (two arbitrarily chosen states from  $X$ ) may be performed in a finite number of steps with probability strictly greater than zero.

Let us consider the following sequence of stages:

- **Stage 0:** In every location in parallel: If the location is full, an agent is chosen, and it performs sequentially action *get* with one of its neighbors in order to remove it (to make possible incoming migration from any other location, in case this location is full). After removing one of its neighbors the agent tries to perform any global action, e.g., *migr* (and fails), until the end of the stage. Otherwise, the trivial null state transition is performed. Final state of the Stage 0 is denoted by  $x_{0e}$ .
- **Stage 1 a:** One location is chosen, at which the sum of agents' energy exceeds the migration threshold in the state  $x_{0e}$  (based on assumption 1 of Theorem 1 there must be at least one). Then one agent from this location  $ag_{gen_1, n_1}$  (possibly possessing the largest energy in the state  $x_{0e}$ ) is chosen. This agent performs a sequence of actions *get* in order to gather all energy from all its neighbors, finally removing them from the system (by bringing their energy to zero).

- **Stage 1 b:** If there are any lymphocytes on the current location, they perform *kill* action, one by one, on the agent  $ag_{gen_1, n_1}$ , failing to remove it from the system, until all lymphocytes are removed. In the end, only one agent is present in the location.
- **Stage 1 c:** Now this agent begins the first migration round in order to visit all locations and to remove the agents (overtaking their energy by performing multiple *get* actions) and remove all lymphocytes. This round is finished at location  $i_1$ . Now, agent  $ag_{gen_1, n_1}$  possesses the total energy of the system which equals 1. Final state of the Stage 1 is denoted by  $x_{1e}$ . Note, that the state matrix has only one positive entry  $x_{1e}(i_1, gen_1, n_1) = 1$ .
- **Stage 2 a:** The agent performs *clo* action producing one of the agents ( $ag_{gen_2, n_2}$ ) that will be present on the location  $i_2$ , one of the locations in the state  $x_e$  containing total energy greater than the migration threshold  $e_{migr}$ . Now it passes all of its energy to this newly produced agent, finally being removed from the system. The purpose of the Stage 2 is to ensure that the agent recreating the population at the last location  $i_2$  will be one of the agents present on this location in the state  $x_e$ . Otherwise if  $i_2$  is full in the state  $x_e$ ,  $ag_{gen_1, n_1}$  could not recreate this population. If  $ag_{gen_1, n_1}$  is active at the location  $i_2$  at the state  $x_e$  (i.e.  $x_e(i_2, gen_1, n_1) > 0$ ), the Stage 2 may be omitted (in this case  $ag_{gen_1, n_1}$  takes the role of  $ag_{gen_2, n_2}$  in the following stages).
- **Stage 3:** Next, the agent  $ag_{gen_2, n_2}$  begins the second migration round (starting migration from the location  $i_1$ ) visiting all locations. In every visited location it performs *clo* operation producing one of the agents that will be present on this location in the state  $x_e$ . The cloned agent on each non-empty location (denoted by  $ag_{gen_i^{first}, n_i^{first}}$ ) will receive the total energy that should be assigned to its location, by the sequence of *get* operations. The agent finishes the migration after recreating the population on the location  $i_2$  (one of the islands containing a total energy in the state  $x_e$  greater than the migration threshold  $e_{migr}$ ).
- **Stage 4 a:** In the system, the following sequence of actions assigned with the consecutive locations labeled by  $i \in Loc$ , non empty in the state  $x_e$ , is performed: every agent  $ag_{gen_i^{first}, n_i^{first}}$  perform a cloning action *clo* to produce an agent with the genotype of one of lymphocytes existing in the location in the state  $x_e$ . Now it performs a sequence of action *get* to remove the agent (and the appropriate lymphocyte is performed). The lymphocyte performs a sequence of *give* actions to adjust its energy to the level observed in the state  $x_e$ . This is repeated until all the lymphocytes present in  $x_e$  are recreated.

- **Stage 4 b:** In the system, the following sequence of actions assigned with the consecutive locations labeled by  $i \in Loc$ , non empty in the state  $x_e$ , is performed: every agent  $ag_{gen_i^{first}, n_i^{first}}$  performs a sequence of cloning actions, recreating the population of agents on its location in the state  $x_e$ .
- **Stage 5:** In every location in parallel: agent  $ag_{gen_i^{first}, n_i^{first}}$  performs a sequence of *get* actions with its neighbors in order to pass to them sufficient amount of energy, required in the state  $x_e$ .

In the extended version of this paper we will show that every of aforementioned stages requires performing at most finite number of Markov chain steps by estimating their upper bounds. Moreover, we will show, that every aforementioned sequences have non-zero probabilities by estimating its lower bounds.

**Remark 1.** *Concluding the proof of Theorem 1 will lead us to the statement that every possible state of iEMAS is reachable after performing a finite sequence of transitions, independently on the initial population. Therefore also the states containing the extrema are reachable. Thus given the assumption of Theorem 1, iEMAS satisfies asymptotic guarantee of success (Horst and Pardalos, 1995; Rinnoy Kan and Timmer, 1987).*

**Remark 2.** *Immediately from the ergodic theorem (Billingsley, 1995) there will exist a strictly positive limit  $\hat{\xi} \in \mathcal{M}(X)$  (i.e.,  $\hat{\xi}(x) > 0, \forall x \in X$ ) of the sequence  $\{\xi_t\}$  by  $t \rightarrow +\infty$ . This limit probability distribution will not depend on the initial probability distribution  $\xi_0$ .*

## CONCLUSIONS

In the course of this contribution, a formal model for iEMAS has been recalled and adjusted for a discrete system state space. The space of states and the transition functions allowing to construct a uniform Markov chain model have been proposed. This model based on stationary Markov chains allows a better understanding of the behavior of the proposed complex systems as well as their constraints.

One of the main implications of the analysis conducted here is the formulation and proof draft of Theorem 1 stating that the Markov chain based model of EMAS is stationary and ergodic. This will lead to an important conclusion stated in Remark 1, namely that EMAS possesses the feature of asymptotic guarantee of success.

A similar proof for EMAS ergodicity has already been formulated and submitted for publication. In the near future we will follow with preparing a full formal proof of iEMAS ergodicity.

## REFERENCES

Billingsley, P. (1995). *Probability and Measure*. Wiley-Interscience.

Byrski, A. and Kisiel-Dorohinicki, M. (2005). Immunological selection mechanism in agent-based evolutionary computation. In *Proc. of IIS: IIPWM '05 conference : Gdansk, Poland*, Advances in Soft Computing. Springer.

Byrski, A. and Schaefer, R. (2009). Stochastic model of evolutionary and immunological multi-agent systems: Mutually exclusive actions. *Fundamenta Informaticae*, 95(2-3):263–285.

Cetnarowicz, K., Kisiel-Dorohinicki, M., and Nawarecki, E. (1996). The application of evolution process in multi-agent world (MAW) to the prediction system. In Tokoro, M., editor, *Proc. of the 2nd Int. Conf. on Multi-Agent Systems (ICMAS'96)*. AAAI Press.

Davis, T. E. and Principe, J. C. (1991). A simulated annealing like convergence theory for the simple genetic algorithm. In *Proc. of the Fourth International Conference on Genetic Algorithms*, pages 174–181, San Diego, CA.

Goldberg, D. and Segrest, P. (1987). Finite Markov chain analysis of genetic algorithms. In *Proceedings of the Second International Conference on Genetic Algorithms on Genetic algorithms and their application*, pages 1–8, Hillsdale, NJ, USA. L. Erlbaum Associates Inc.

Horn, J. (1993). Finite Markov Chain Analysis of Genetic Algorithms with Niching. In *Proceedings of the Fifth International Conference on Genetic Algorithms*, pages 110–117. Morgan Kaufmann.

Horst, R. and Pardalos, P. (1995). *Handbook of Global Optimization*. Kluwer.

Mahfoud, S. (1991). Finite Markov Chain Models of an Alternative Selection Strategy for the Genetic Algorithm. *Complex Systems*, 7:155–170.

Rinnoy Kan, A. and Timmer, G. (1987). Stochastic global optimization methods. *Mathematical Programming*, 39:27–56.

Rudolph, G. (1994). Massively parallel simulated annealing and its relation to evolutionary algorithms. *Evolutionary Computation*, 1:361–383.

Schaefer, R., Byrski, A., and Smolka, M. (2009). Stochastic model of evolutionary and immunological multi-agent systems: Parallel execution of local actions. *Fundamenta Informaticae*, 95(2-3):325–348.

Suzuki, J. (1993). A Markov Chain Analysis on a Genetic Algorithm. In Forrest, S., editor, *Proc. of the 5th ICGA*, pages 146–154. Morgan Kaufmann.

Vose, M. (1998). *The Simple Genetic Algorithm: Foundations and Theory*. MIT Press, Cambridge, MA, USA.